Precision medicine is changing the way clinical trials are designed - and how laboratory partners support them.
A single study may now involve routine safety testing alongside flow cytometry, immunology, genomics, pathology services, multiplex immunoassays and highly specialized biomarker assays.
This analytical diversity creates tremendous opportunities for scientific discovery, but it also introduces significant complexity.
As trials become increasingly personalized, laboratory requirements continue to grow.
Sponsors must coordinate multiple testing methodologies, maintain assay consistency, manage evolving biomarker strategies and ensure data comparability throughout the study lifecycle.
Without careful planning, analytical diversity can create operational bottlenecks that delay progress and increase risk.
According to the whitepaper, many of the most avoidable problems in clinical trials stem from issues identified too late in the process. Early central laboratory involvement can help sponsors evaluate feasibility, identify testing challenges and optimize analytical strategies before protocols are finalized.
This proactive approach helps reduce costly amendments and mitigate downstream risks.
As specialized testing becomes central to drug development, sponsors need laboratory partners with both breadth and depth of scientific expertise.
The ability to coordinate diverse analytical requirements within a unified framework may become one of the most important differentiators in successful clinical trial execution.